Who Optimizes SG&A Costs Better? Viatris Inc. or MorphoSys AG

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Viatris Inc. and MorphoSys AG have taken different paths in optimizing these costs. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, MorphoSys AG maintained a leaner approach, with expenses reaching around $199 million at their highest in 2021. This stark difference highlights Viatris's expansive operations compared to MorphoSys's more focused strategy. Despite Viatris's larger scale, MorphoSys's ability to keep costs relatively low could be seen as a strategic advantage in a market where efficiency is key. As the industry evolves, these companies' approaches to SG&A optimization will continue to shape their financial health and competitive standing.